Main Street Research LLC Has $2.12 Million Stake in Johnson & Johnson (NYSE:JNJ)

Main Street Research LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 20.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,806 shares of the company's stock after acquiring an additional 2,166 shares during the period. Main Street Research LLC's holdings in Johnson & Johnson were worth $2,124,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Mraz Amerine & Associates Inc. lifted its holdings in Johnson & Johnson by 0.5% in the first quarter. Mraz Amerine & Associates Inc. now owns 24,242 shares of the company's stock worth $3,969,000 after acquiring an additional 124 shares during the last quarter. Topsail Wealth Management LLC increased its stake in shares of Johnson & Johnson by 5.3% in the first quarter. Topsail Wealth Management LLC now owns 2,684 shares of the company's stock valued at $445,000 after purchasing an additional 134 shares during the period. Moloney Securities Asset Management LLC increased its stake in shares of Johnson & Johnson by 5.6% in the first quarter. Moloney Securities Asset Management LLC now owns 35,569 shares of the company's stock valued at $5,899,000 after purchasing an additional 1,872 shares during the period. Banque Pictet & Cie SA increased its stake in shares of Johnson & Johnson by 15.0% in the first quarter. Banque Pictet & Cie SA now owns 205,333 shares of the company's stock valued at $34,052,000 after purchasing an additional 26,859 shares during the period. Finally, Slagle Financial LLC increased its stake in shares of Johnson & Johnson by 0.6% in the first quarter. Slagle Financial LLC now owns 14,114 shares of the company's stock valued at $2,341,000 after purchasing an additional 86 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.82 during mid-day trading on Friday, hitting $156.87. The company's stock had a trading volume of 7,866,488 shares, compared to its average volume of 8,066,975. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $377.44 billion, a P/E ratio of 17.45, a P/E/G ratio of 2.15 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock's fifty day moving average price is $153.75 and its two-hundred day moving average price is $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Analysts Set New Price Targets

Several brokerages have commented on JNJ. Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Raymond James Financial dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Finally, Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.